Novo Nordisk (NVO) is showing strong potential with its weight loss treatments, particularly the oral pill version of Wegovy. The company's market performance has been exceptional, and recent development in drug approvals and wider accessibility suggest continued growth. Financial analysis indicates that NVO is currently trading below its intrinsic value, presenting a potential buying opportunity for investors.